A new clinical trial conducted at the Washington University School of Medicine in St. Louis has determined that customizing radiation levels in children with medulloblastoma, by either "lowering the dose of radiation or delivering radiation to a smaller area of the brain" could result in a higher rate of survival without the negative adverse events associated with radiation therapy.
Study results conducted on the 464 of 549 children that were able to be evaluated determined that 85% of children were alive beyond 5 years after treatment, and 81% did not experience a cancer-related event during those 5 years.
To read more about this trial, click here.
No comments:
Post a Comment